Diabetes

New drug application filed for fixed-ratio combination of insulin glargine and lixisenatide.

Sanofi has submitted a new drug application to the FDA for a fixed-ratio combination of insulin glargine and lixisenatide.

Patients with cerebral palsy are often faced with secondary health conditions such as diabetes, asthma, and hypertension.

Protein linked to diabetic enteropathy.

Arguments persist regarding which diabetes patients should be prescribed blood pressure-lowering treatments.

High blood pressure is an established risk factor for cardiovascular events in patients with diabetes.

Basaglar improves glycemic control among adult and pediatric patients with type 1 diabetes and among adults with type 2 diabetes.

The FDA has approved insulin glargine injection, a long-acting human insulin analog to improve glycemic control among adult and pediatric patients with type 1 diabetes and adults with type 2 diabetes.

Diabetes is a known risk factor for cognitive decline and dementia.

The mainstays of diabetes treatment are ripe for disruption.

REMS deemed unnecessary to ensure drug benefits outweigh risks.

C-reactive protein is useful in the diagnosis and treatment of some acute or chronic inflammatory conditions.

Proper drug selection may alter outcomes and health care system costs.

The FDA is eliminating the Risk Evaluation and Mitigation Strategy for type 2 diabetes medications containing rosiglitazone.

Diabetes has a tremendous global impact, but developing nations often struggle to help patients deal with their disease.

Researchers target effect of various medical conditions on platelet function.

Needle mechanism that delivers insulin fails to deploy or is delayed.

Through a voluntary field safety notification, Insulet Corporation is notifying consumers and health care professionals about a slight increase in reports in which the OmniPod's needle mechanism to deliver insulin fails to deploy or is delayed.

Warnings about the risk of ketoacidosis and serious urinary tract infections have been added to the labels of SGLT2 inhibitors.

Potentially game changing drug may alter diabetes disease course.

Warnings about the risk of ketoacidosis and serious urinary tract infections have been added to the labels of SGLT2 inhibitors.

Is metformin the magic cure to slow the aging process?

People with sleep schedule disruptions more likely to be resistant to insulin.

Once-daily tablets treat type 2 diabetes in adults as an adjunctive treatment to diet and exercise to improve glycemic control.

Shifts in sleep schedules may increase an individual's risk for diabetes.

Janssen Research and Development LLC has submitted a new drug application to the FDA for canagliflozin and metformin hydrochloride extended release (Invokamet XR).

What you eat and drink on Thanksgiving can significantly affect some medications.

Pharmacists help set goals for patients with type 2 diabetes.

Women with type 2 diabetes have greater difficulty with exercise than those without the condition.

Approximately 29.1 million individuals in the United States have diabetes, and an estimated 8.1 million cases are undiagnosed.